SORAFEKAST blocks multiple tyrosine kinases involved in tumour growth and angiogenesis.
Recommended for:
Patients with unresectable or metastatic liver cancer
Progressive renal cell carcinoma
Differentiated thyroid cancer refractory to radioactive iodine
Hepatocellular carcinoma
Renal cell carcinoma
Differentiated thyroid carcinoma (radioiodine-refractory)
Take orally with or without food. The dosage and treatment duration should be determined by the physician based on cancer type and individual condition.
Contraindications:
Hypersensitivity to components
Pregnancy and breastfeeding
Severe liver impairment
Paediatric use
Side Effects:
Diarrhoea, appetite loss
Fatigue
Skin rash or reactions
High blood pressure
Thyroid dysfunction